Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival.

There was also a borderline significant trend toward an increased objective RR in patients with grade 3 to 4 immune-related adverse events (4 of 15 [27%] vs 2 of 36 [6%]; P < .05).

also in 231 other papers

When patients were stratified based on their baseline ALC, there was a nonsignificant trend toward an increased rate of clinical benefit at Week 24 for patients with a high versus low ALC (10 of 21 [48%] patients vs 7 of 30 [23%]; P = .07).

also in 5,406 other papers